Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Pfizer

Innovative Health sales up 8% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer
2Q Revenues: $13.5 billion (+4%)
2Q Earnings: $3.9 billion (+20%)
YTD Revenues: $26.4 billion (+3%)
YTD Earnings: $7.4 billion (20%)
Comments: Innovative Health sales were $8.3 billion in the quarter, up 8%. Growth from key brands included Eliquis, Ibrance and Xeljanz globally, Prevnar 13/Prevenar 13 primarily in emerging markets and the U.S., as well as Xtandi in the U.S. Operational revenue growth for Eliquis, Ibrance, Xeljanz and Xtandi was 42%, 19%, 37% and 21%, respectively. Essential Health sales were $5.2 billion, down 1% with a 12% operational decline in the Legacy Established Products portfolio in developed markets; a 17% operational decline in the Sterile Injectable Pharmaceuticals portfolio in developed markets, primarily due to continued legacy Hospira product shortages in the U.S.; 10% operational growth in emerging markets, reflecting growth across all portfolios; and 44% operational growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. as well as in developed Europe.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters